- ISIN
- US45166A1025
- CUSIP
- 45166A102
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 23, 2019
Highlights
- Market Cap
- $3.04B
- Enterprise Value
- $2.91B
- EPS (TTM)
- -$1.58
- Total Revenue (TTM)
- $225.27M
- Gross Profit (TTM)
- $215.25M
- EBITDA (TTM)
- -$157.90M
- Year Range
- $20.50 - $39.28
- Target Price
- $58.67
- ROA (TTM)
- -13.59%
- ROE (TTM)
- -14.94%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
IDYA Performance Chart
IDEAYA Biosciences, Inc. (IDYA) is down 1.0% since the beginning of the year. At $34 per share, IDYA is trading 12.9% below its 52-week high of $39. Investors who bought $1,000 worth of IDYA shares 5 years ago would now be looking at an investment worth $1,574.
Loading charts...
Returns By Period
IDEAYA Biosciences, Inc. (IDYA) has returned -0.98% so far this year and 57.96% over the past 12 months.
IDEAYA Biosciences, Inc.
- 1D
- 9.61%
- 1M
- 17.63%
- YTD
- -0.98%
- 6M
- -3.58%
- 1Y
- 57.96%
- 3Y*
- 11.82%
- 5Y*
- 9.49%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
IDYA Monthly Returns History
Based on dividend-adjusted daily data since May 23, 2019, IDYA's average daily return is +0.16%, while the average monthly return is +2.86%. At this rate, an investment would double in approximately 2.0 years.
Historically, 53% of months were positive and 47% were negative. The best month was May 2020 with a return of +76.4%, while the worst month was Mar 2020 at -41.1%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 8 months.
On a daily basis, IDYA closed higher 50% of trading days. The best single day was Nov 13, 2019 with a return of +47.4%, while the worst single day was Aug 15, 2022 at -34.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.88% | 0.03% | 3.48% | -12.67% | 1.27% | 16.15% | -0.98% | ||||||
| 2025 | -5.25% | -15.52% | -20.37% | 22.89% | -1.19% | 5.68% | 15.84% | 0.82% | 10.84% | 17.09% | 11.80% | -2.95% | 34.51% |
| 2024 | 22.34% | 2.69% | -1.83% | -7.36% | -10.09% | -3.94% | 22.61% | -8.25% | -19.80% | -11.14% | -2.81% | -6.07% | -27.77% |
| 2023 | -6.27% | 3.64% | -22.21% | 32.99% | 25.08% | 2.89% | -4.85% | 31.31% | -8.11% | 0.70% | 15.75% | 13.13% | 95.82% |
| 2022 | -29.91% | -20.34% | -15.23% | -14.30% | 16.27% | 23.77% | 8.12% | -34.12% | 51.78% | 13.20% | 5.86% | 1.62% | -23.14% |
| 2021 | 25.57% | 8.48% | 23.23% | -12.55% | -1.95% | 4.17% | 16.72% | -4.08% | 8.47% | -15.89% | 2.61% | 7.45% | 68.86% |
Benchmark Metrics
IDEAYA Biosciences, Inc. has an annualized alpha of 26.74%, beta of 1.00, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since May 23, 2019.
- This stock participated in 87.15% of S&P 500 Index downside but only 85.33% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 26.74%
- Beta
- 1.00
- R²
- 0.07
- Upside Capture
- 85.33%
- Downside Capture
- 87.15%
Return for Risk
Risk / Return Rank
IDYA ranks 75 for risk / return — better than 75% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for IDEAYA Biosciences, Inc. (IDYA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| IDYA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.85 | ||
| Sortino ratioReturn per unit of downside risk | -0.92 | ||
| Omega ratioGain probability vs. loss probability | 1.23 | 1.37 | -0.14 |
| Calmar ratioReturn relative to maximum drawdown | 2.15 | 2.78 | -0.63 |
| Martin ratioReturn relative to average drawdown | 4.76 | 12.44 | -7.68 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the IDEAYA Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the IDEAYA Biosciences, Inc. was 78.36%, occurring on Mar 17, 2020. Recovery took 64 trading sessions.
The current IDEAYA Biosciences, Inc. drawdown is 27.37%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
COVID crash2020 | -78.36%Mar 2020 | 9mo 29d | 3mo 2d | 1y 26dMay 2019 - Jun 2020 |
Bear market2022 | -69.42%May 2022 | 7mo 18d | 1y 3mo | 1y 11moSep 2021 - Aug 2023 |
2025 selloff2025 | -69.23%Apr 2025 | 1y 1mo | — | 2y 4moFeb 2024 - now |
2020 bear market2020 | -39.58%Aug 2020 | 2mo 4d | 5mo 1d | 7mo 5dJun 2020 - Jan 2021 |
2021 bear market2021 | -30.49%Jul 2021 | 3mo 3d | 1mo 26d | 4mo 29dApr 2021 - Sep 2021 |
Drawdown Indicators
| IDYA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -78.36% | -56.78% | -21.58% |
Max Drawdown (1Y)Largest decline over 1 year | -27.10% | -9.10% | -18.00% |
Max Drawdown (3Y)Largest decline over 3 years | -69.23% | -18.90% | -50.33% |
Max Drawdown (5Y)Largest decline over 5 years | -69.42% | -25.43% | -43.99% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -27.37% | -1.80% | -25.57% |
Average DrawdownAverage peak-to-trough decline | -32.37% | -10.71% | -21.66% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.22% | 2.03% | +10.19% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of IDEAYA Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how IDEAYA Biosciences, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for IDYA relative to other companies in the Biotechnology industry. Currently, IDYA has a P/S ratio of 13.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for IDYA in comparison with other companies in the Biotechnology industry. Currently, IDYA has a P/B value of 3.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with IDYA
Add IDEAYA Biosciences, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with IDYA